Atom Investors LP Crinetics Pharmaceuticals, Inc. Transaction History

Atom Investors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $169,872 - $228,760	4,887 New	4,887 $228,000
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $285,751 - $547,346	17,893 New	17,893 $532,000
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $1.05 Million - $1.45 Million	-68,580 Reduced 84.18%	12,886 $206,000
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $504,060 - $619,906	32,541 Added 66.51%	81,466 $1.49 Million
Q3 2022 Nov 08, 2022	SELL	$18.11 - $22.37 $175,232 - $216,452	-9,676 Reduced 16.51%	48,925 $961,000
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $116,501 - $195,276	7,065 Added 13.71%	58,601 $1.09 Million
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $198,031 - $326,895	11,547 Added 28.88%	51,536 $1.13 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $773,787 - $1.14 Million	39,989 New	39,989 $1.14 Million

241

79.6M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $3.01B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

Stay updated on Atom Investors LP with notifications on news.